Skip to content

Released Nov 4, 2021, after the close

10-Q filed Nov 4, 2021, 35 days after period end · 0000950170-21-003066

Q3 2021 · 10-Q
Revenue$14.23M+88.2% vs Q3 2020+6.1% vs Q2 2021
Net Income-$43.31MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.45N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$54,623,000N/M
Operating Cash Flowderived-$33,375,000N/M
Free Cash Flowderived-$48,110,000N/M
Margins · derived
Operating margin-384.0%+32.6 pt vs Q3 2020
Net margin-304.4%+472.0 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$14.23M$7.56M$2.43M$1.03M
Net Income-$43.31M-$58.68M-$26.61M-$16.78M
EPS Diluted-$0.45-$0.68-$0.40-$0.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR